YBS Biographer Newsletter
Autumn/Winter 2012 Join our mailing list and download the latest and previous copies of our quarterly newsletter.
> Latest Edition

Latest News

Show/Hide Search


Page 1 of 2:  < Prev|1|2|Next >

Date Posted: 11 April 2018
We are pleased to announce the successful completion of a three-day inspection by the United States Food and Drug Administration (FDA) of our bioanalytical facility in York.    Read More ...

Date Posted: 03 October 2016
We are pleased to announce that YBS underwent another successful routine GLP/GCP compliance inspection by the MHRA of our facilities in York on 15-16 September 2016.   Read More ...

Date Posted: 01 June 2016
As part of Unilabs York Bioanalytical Solutions’ (Unilabs YBS) commitment to providing an unparalleled service to its clients, YBS is pleased to announce a significant expansion of its Metabolism and Discovery Services facility based at Discovery Park in Sandwich Kent.    Read More ...

Date Posted: 01 May 2014
We are pleased to announce that YBS underwent a successful routine GLP/GCP compliance inspection by the MHRA of our facilities in York on 24-25 April 2014.    Read More ...

Date Posted: 25 March 2013
PRESS RELEASE   Read More ...

Date Posted: 21 March 2012
PRESS RELEASE   Read More ...

Date Posted: 08 November 2011
Dr Tim Leunig explores the ramifications of Pfizer shutting its operations in Kent, and examines the choices on hand for locals.   Read More ...

Date Posted: 19 October 2011
As part of Unilabs York Bioanalytical Solutions’ (Unilabs YBS) commitment to providing an unparalleled service to its clients, YBS is pleased to announce the opening of a new facility on the Discovery Park in Sandwich Kent. The new facility will offer discovery bioanalysis and biotransformation services.    Read More ...

Date Posted: 28 June 2011
Unilabs has been selected by Biogen Idec to provide a companion diagnostic anti-JCV antibody assay test, called STRATIFY-JCV. The test is a highly sensitive two-step ELISA assay used to detect anti-JCV antibodies. The presence of anti-JCV antibodies is one in a three-factor risk stratification algorithm, along with prior immunosuppressant use and treatment duration, used to calculate the risk of TYSABRI-treated patients developing progressive multifocal leukoencephalopathy (PML).   Read More ...

Date Posted: 19 April 2011
Unilabs York Bioanalytical Solutions (YBS) has a history of employing cutting edge technology to maintain its place as Europe’s premier, independent bioanalytical facility.   Read More ...

Page 1 of 2:  < Prev|1|2|Next >
Printer Friendly  |   Sitemap © Unilabs Bioanalytical Solutions 2010 - 2017  |   Privacy Policy  |   Website Disclaimer  |   Website Credits